Showing results (131-140 of 143) with videos related to
Sort By:
Pageof 15
International Journal of Cancer|July 13, 2024
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profilingJacqueline A Turner, Robert J Van Gulick, William A Robinson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.The New England Journal of Medicine|September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.The New England Journal of Medicine|June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanomaF Stephen Hodi, Steven J O'Day, David F McDermott, et al.The New England Journal of Medicine|September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.The New England Journal of Medicine|June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
Melanoma, version 4.2014Daniel G Coit, John A Thompson, Robert Andtbacka, et al.Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
NCCN Guidelines Insights: Melanoma, Version 3.2016Daniel G Coit, John A Thompson, Alain Algazi, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Alain Algazi, et al.The New England Journal of Medicine|September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaJeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.Pageof 15